449 related articles for article (PubMed ID: 10493279)
21. [Preclinical pharmacology and clinical uses of topotecan].
Del Tacca M; Di Paolo A; Danesi R
Tumori; 1999; 85(6 Suppl 1):S3-11. PubMed ID: 10786194
[TBL] [Abstract][Full Text] [Related]
22. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.
Garst J; Buller R; Lane S; Crawford J
Clin Lung Cancer; 2005 Nov; 7(3):190-6. PubMed ID: 16354314
[TBL] [Abstract][Full Text] [Related]
23. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
[TBL] [Abstract][Full Text] [Related]
24. Topotecan in the first-line treatment of small cell lung cancer.
Stewart DJ
Oncologist; 2004; 9 Suppl 6():33-42. PubMed ID: 15616148
[TBL] [Abstract][Full Text] [Related]
25. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
[TBL] [Abstract][Full Text] [Related]
27. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
29. The role of topotecan in treating small cell lung cancer: second-line treatment.
von Pawel J
Lung Cancer; 2003 Aug; 41 Suppl 4():S3-8. PubMed ID: 14565508
[TBL] [Abstract][Full Text] [Related]
30. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Choi HJ; Cho BC; Shin SJ; Cheon SH; Jung JY; Chang J; Kim SK; Sohn JH; Kim JH
Cancer Chemother Pharmacol; 2008 Feb; 61(2):309-13. PubMed ID: 17576560
[TBL] [Abstract][Full Text] [Related]
31. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
[TBL] [Abstract][Full Text] [Related]
32. [Topotecan, a recent discovery and prospects for treating tumors of the lung].
Gridelli C
Tumori; 1999; 85(6 Suppl 1):S16-22. PubMed ID: 10786196
[TBL] [Abstract][Full Text] [Related]
33. Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan.
Rocha Lima CM; Chiappori A
Lung Cancer; 2003 Jun; 40(3):229-36. PubMed ID: 12781421
[TBL] [Abstract][Full Text] [Related]
34. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
Herzog TJ
Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
[TBL] [Abstract][Full Text] [Related]
36. Comparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung cancer.
Hacibekiroglu I; Ozkul O; Cakir E; Kostek O; Karatas F; Esenkaya A; Demirci A; Bilir C
J BUON; 2021; 26(1):79-86. PubMed ID: 33721436
[TBL] [Abstract][Full Text] [Related]
37. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life.
Gralla RJ
Oncologist; 2004; 9 Suppl 6():14-24. PubMed ID: 15616146
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
[TBL] [Abstract][Full Text] [Related]
39. Topotecan as first-line therapy for small cell lung cancer.
Greco FA
Lung Cancer; 2003 Aug; 41 Suppl 4():S9-16. PubMed ID: 14565509
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Paik PK; Rudin CM; Pietanza MC; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
Lung Cancer; 2011 Dec; 74(3):481-5. PubMed ID: 21620511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
